Millennium Management’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.31M | Buy |
2,384,713
+731,244
| +44% | +$1M | ﹤0.01% | 3381 |
|
|
2025
Q4 | $2.66M | Sell |
1,653,469
-1,203,768
| -42% | -$2.52M | ﹤0.01% | 3690 |
|
|
2025
Q3 | $7.8M | Buy |
2,857,237
+693,738
| +32% | +$2.31M | ﹤0.01% | 2643 |
|
|
2025
Q2 | $7.88M | Buy |
2,163,499
+959,647
| +80% | +$2.64M | ﹤0.01% | 2516 |
|
|
2025
Q1 | $2.31M | Buy |
1,203,852
+1,034,205
| +610% | +$2.11M | ﹤0.01% | 3651 |
|
|
2024
Q4 | $322K | Buy |
169,647
+149,402
| +738% | +$259K | ﹤0.01% | 5034 |
|
|
2024
Q3 | $26.7K | Sell |
20,245
-25,440
| -56% | -$34K | ﹤0.01% | 5765 |
|
|
2024
Q2 | $46.6K | Sell |
45,685
-3,220,315
| -99% | -$3.98M | ﹤0.01% | 5429 |
|
|
2024
Q1 | $5.98M | Buy |
3,266,000
+666,013
| +26% | +$1.06M | ﹤0.01% | 2705 |
|
|
2023
Q4 | $3.22M | Sell |
2,599,987
-452,738
| -15% | -$462K | ﹤0.01% | 3178 |
|
|
2023
Q3 | $3.48M | Buy |
3,052,725
+1,046,767
| +52% | +$1.34M | ﹤0.01% | 3056 |
|
|
2023
Q2 | $1.84M | Buy |
2,005,958
+1,095,000
| +120% | +$1.06M | ﹤0.01% | 3561 |
|
|
2023
Q1 | $511K | Sell |
910,958
-431,464
| -32% | -$330K | ﹤0.01% | 4593 |
|
|
2022
Q4 | $775K | Sell |
1,342,422
-2,138,436
| -61% | -$670K | ﹤0.01% | 4399 |
|
|
2022
Q3 | $1.1M | Sell |
3,480,858
-1,873,317
| -35% | -$735K | ﹤0.01% | 4254 |
|
|
2022
Q2 | $1.89M | Buy |
5,354,175
+2,722,361
| +103% | +$1.14M | ﹤0.01% | 3763 |
|
|
2022
Q1 | $1.89M | Buy |
2,631,814
+707,980
| +37% | +$1.51M | ﹤0.01% | 3942 |
|
|
2021
Q4 | $4.35M | Buy |
+1,923,834
| New | +$5.25M | ﹤0.01% | 3043 |
|
|
2021
Q3 | – | Sell |
-264,954
| Closed | -$1M | – | 6729 |
|
|
2021
Q2 | $1M | Sell |
264,954
-1,083,339
| -80% | -$3.65M | ﹤0.01% | 4663 |
|
|
2021
Q1 | $4.56M | Sell |
1,348,293
-598,214
| -31% | -$2.15M | ﹤0.01% | 2675 |
|
|
2020
Q4 | $5.45M | Sell |
1,946,507
-260,771
| -12% | -$761K | ﹤0.01% | 2357 |
|
|
2020
Q3 | $5.54K | Buy |
+2,207,278
| New | +$19.4M | 0.01% | 1745 |
|
|
2020
Q2 | – | Sell |
-860,215
| Closed | -$6.52M | – | 4132 |
|
|
2020
Q1 | $6.52M | Buy |
860,215
+189,157
| +28% | +$1.47M | 0.01% | 1139 |
|
|
2019
Q4 | $4.24M | Buy |
671,058
+622,424
| +1,280% | +$2.96M | 0.01% | 2066 |
|
|
2019
Q3 | $190K | Sell |
48,634
-127,501
| -72% | -$546K | ﹤0.01% | 3809 |
|
|
2019
Q2 | $852K | Buy |
176,135
+141,210
| +404% | +$803K | ﹤0.01% | 2895 |
|
|
2019
Q1 | $286K | Sell |
34,925
-202,602
| -85% | -$1.39M | ﹤0.01% | 3570 |
|
|
2018
Q4 | $1.31M | Sell |
237,527
-19,925
| -8% | -$156K | ﹤0.01% | 2450 |
|
|
2018
Q3 | $2.27M | Sell |
257,452
-133,518
| -34% | -$1.19M | ﹤0.01% | 2361 |
|
|
2018
Q2 | $3.9M | Sell |
390,970
-267,052
| -41% | -$2.67M | 0.01% | 1963 |
|
|
2018
Q1 | $6.27M | Sell |
658,022
-366,470
| -36% | -$5.13M | 0.01% | 1658 |
|
|
2017
Q4 | $15.2M | Buy |
1,024,492
+240,692
| +31% | +$3.99M | 0.02% | 1063 |
|
|
2017
Q3 | $15.4M | Buy |
783,800
+196,886
| +34% | +$3.03M | 0.02% | 947 |
|
|
2017
Q2 | $8.43M | Buy |
586,914
+156,600
| +36% | +$1.98M | 0.02% | 1154 |
|
|
2017
Q1 | $3.96M | Buy |
430,314
+119,426
| +38% | +$1.17M | 0.01% | 1593 |
|
|
2016
Q4 | $3.24M | Buy |
310,888
+277,887
| +842% | +$2.39M | 0.01% | 1609 |
|
|
2016
Q3 | $299K | Sell |
33,001
-21,182
| -39% | -$180K | ﹤0.01% | 2815 |
|
|
2016
Q2 | $405K | Buy |
+54,183
| New | +$473K | ﹤0.01% | 2589 |
|
|
2016
Q1 | – | Sell |
-282,541
| Closed | -$3.65M | – | 3226 |
|
|
2015
Q4 | $3.65M | Buy |
282,541
+70,455
| +33% | +$719K | 0.01% | 1572 |
|
|
2015
Q3 | $2.05M | Buy |
212,086
+185,586
| +700% | +$1.7M | ﹤0.01% | 1886 |
|
|
2015
Q2 | $273K | Buy |
26,500
+6,172
| +30% | +$52.7K | ﹤0.01% | 2923 |
|
|
2015
Q1 | $226K | Sell |
20,328
-94,680
| -82% | -$1.01M | ﹤0.01% | 3234 |
|
|
2014
Q4 | $1.34M | Buy |
115,008
+69,941
| +155% | +$1M | ﹤0.01% | 2289 |
|
|
2014
Q3 | $997K | Buy |
+45,067
| New | +$1.04M | ﹤0.01% | 2309 |
|
Other funds holding AKBA
VCM
VPM
Millennium Management's AKBA Position: Q1 2026 in Review
Millennium Management increased its Akebia Therapeutics (AKBA) stake by 44% in Q1 2026, buying an estimated $1M and bringing the position to 2,384,713 shares worth $3.31M. The position accounts for ﹤0.01% of the portfolio, ranked #3381.
Millennium Management first reported a position in AKBA in Q3 2014 and has held it in 44 quarters since. The position peaked at $15.4M in Q3 2017. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.
- Millennium Management held 2,384,713 shares of Akebia Therapeutics worth $3.31M as of Q1 2026.
- Millennium Management bought 731,244 Akebia Therapeutics shares in Q1 2026, an estimated $1M.
- Akebia Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #3381 holding.
- Millennium Management first reported a position in Akebia Therapeutics in Q3 2014 and has held it in 44 quarters since.
- Millennium Management's Akebia Therapeutics position peaked at $15.4M in Q3 2017.
- 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.
Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.